<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793203</url>
  </required_header>
  <id_info>
    <org_study_id>4176</org_study_id>
    <nct_id>NCT05793203</nct_id>
  </id_info>
  <brief_title>Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients</brief_title>
  <acronym>ElastOLT</acronym>
  <official_title>Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A lot of different early and late complications may occur after liver transplantation. They&#xD;
      could be related to surgical procedure, to infectious diseases or immuno-mediated diseases&#xD;
      (acute cellular rejection, ACR). Almost all of those complications are characterized by an&#xD;
      elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum&#xD;
      bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this&#xD;
      scenario there is a lack of biomarker that could predict the development of ACR and/or EAD.&#xD;
&#xD;
      The aim of this study is to explore the prognostic role of non-invasive instrumental and&#xD;
      biological marker in the early post-transplant phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early Allograft dysfunction (EAD)</measure>
    <time_frame>2 weeks from Liver transplantation</time_frame>
    <description>Olthoff criteria: bilirubina≥ 10 mg/dL in 7th post-operative day, international normalized ratio (INR) ≥ 1.6 in 7th post-operative day 7; ALT or AST&gt; 2000 IU/L during the first 7 days after liver transplantation</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rejection Acute Hepatic</condition>
  <condition>Transplant; Failure, Liver</condition>
  <condition>Liver Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for liver transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients eligible for liver transplantation following National and International&#xD;
             Guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No agreement or inability to give informed consent&#xD;
&#xD;
               -  Re-transplant patients&#xD;
&#xD;
               -  Liver transplant in fulminant hepatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Liguori, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Miele, MD, PhD</last_name>
    <phone>+390630151</phone>
    <email>luca.miele@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00181</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Liguori, MD</last_name>
      <phone>+390630159223</phone>
      <email>lig.antonio91@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

